Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy

CALGARY, Feb. 4 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY)
('Oncolytics') reported today that Dr. Kevin Harrington and his research group
at The Institute of Cancer Research, London, U.K. published the results of
their work testing combination treatment schedules of reovirus and radiation
in human and murine tumour cells in vitro and in vivo. The paper, entitled
"Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and
Radiotherapy" appears online in the February 1, 2008 issue of Clinical Cancer
Research.

The effect of different schedules of reovirus and radiotherapy on viral
replication and cytotoxicity was tested in vitro and the combination was
assessed in three tumour models in vivo.

CNW Group